Reading Time: 3 minutes

Acumen Research and Consulting, a global provider of market research studies, recently added a forthcoming report titled “Pigmented Villonodular Synovitis Treatment Market – Global Industry Analysis, Market Size, Opportunities and Forecast, 2021-2030

LOS ANGELES, April 28, 2021 (GLOBE NEWSWIRE) — Pigmented villonodular synovitis (PVNS) is a condition that causes the synovium the thin layer of tissue that lines the joints and tendons. PVNS usually affects the knee, although it can affect other joints as well.

Market Dynamics

Increasing in-patients in hospitals related suffering from rare condition and demand for advanced treatment are factors expected to drive the growth of global pigmented villonodular synovitis treatment market. By 2040, nearly 80 million U.S. adults will have some form of arthritis diagnosed, according to the Centers for Disease Control and Prevention. The mass or tumor that results from this overgrowth is not cancerous and does not spread (metastasize) to other areas of the body. Increasing R&D activities related to development of advanced treatment by the government and high spending on healthcare sector are factors expected to impact the growth of pigmented villonodular synovitis treatment market. Government is spending high on R&D activities; their collaborative approach with private players and high clinical trials for development of advance cure is gaining traction.


PVNS is most normally monoarticular (~70% knee joint) yet sporadically it very well may be oligoarticular. The histology of PVNS can appear to be like some forceful neoplasms (rhabdomyosarcoma, synovial sarcoma, epithelioid sarcoma) and imaging, subsequently, has an urgent part in directing the pathologist.

Radiographs show vague highlights like joint emission and bone disintegrations, CT and ultrasound can likewise exhibit the hypertrophic synovium as a marginally hyperdense/echogenic delicate tissue mass. X-ray is the best methodology showing the mass-like synovial expansion with lobulated edges, with low sign power and “sprouting” ancient rarity on slope reverberation because of the hemosiderin statement.

All synovial films might be influenced, and pathologists will in general characterize the range of histologically indistinguishable substances under the umbrella of tenosynovial monster cell tumor. Different destinations with a synovial coating that might be influenced incorporate bursae and ligament sheaths. The condition is then known as pigmented villonodular bursitis (PVNB) when in a bursa and tenosynovial monster cell tumor when in a ligament sheath.


PVNS/B/TS are separated into a restricted and diffuse structure: generally normal and typically extra-articular (PVNB and PVNTS)
2 diffuse (for example includes the entirety of the coterminous synovium): is the most well-known type of an intra-articular illness, albeit nearby intra-articular association is additionally in some cases seen

Regularly PVNS is a monoarticular condition and joints with huge synovial surfaces are typically most as often as possible influenced. The rest of this article centers around intra-articular infection (PVNS).

Market Segment Analysis

The global pigmented villonodular synovitis treatment market is segmented into type of treatment and end user. The type of treatment segment is bifurcated into drug therapy, radiation therapy, and surgical operation. Among type of treatment the drug therapy segment is expected to account for major revenue share in the global pigmented villonodular synovitis treatment market. The end use segment is divided into hospitals, surgical clinics, and others. The players profiled in the report are Plexxikon, Inc., Novartis AG, F. Hoffmann-La Roche Ltd., and Bristol-Myers Squibb Company.

Browse Upcoming Market Research [email protected]

Segment Analysis by Region 

The market in North America is expected to account for major revenue share in the global pigmented villonodular synovitis treatment market due to high patient pool suffering from arthritis. In addition, availability of advanced infrastructure for R&D activities and introduction of new drugs are factors expected to support the growth of target market. Major player’s inclination towards increasing the customer base and enhance the product portfolio is expected to augment the pigmented villonodular synovitis treatment market growth.

The market in Asia Pacific is expected to witness faster growth in the pigmented villonodular synovitis treatment market due to changing government regulations related to healthcare sector. In addition, favorable business policies and players approach towards emerging economies in order to track the untapped market are factor expected to support the regional market growth.

Competitive Landscape      

The global pigmented villonodular synovitis treatment market is highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.

INQUIRY BEFORE [email protected]


Would like to place an order or any question, please feel free to contact at [email protected] | +1 407 915 4157

For Latest Update Follow Us:

Powered by WPeMatico